Company intelligence
DiaMedica Therapeutics Inc.
Redefine What’s Possible: a Potential New Treatment Paradigm for Patients with Preeclampsia and Ischemic Stroke
Biotechnology Research
Minneapolis, US
46 employees
2 public signals
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with a focus on preeclampsia and acute ischemic stroke. For more information please visit www.diamedica.com.
Verified activity
Signals from DiaMedica Therapeutics Inc.
2 published signals
Partnerships
DiaMedica Therapeutics Inc. partnered with the Preeclampsia Foundation to advance the development of DM199, a recombinant human KLK1 protein as a potential treatment for ischemic disorders including preeclampsia, fetal growth restriction, and acute ischemic stroke.
Reported by DiaMedica Therapeutics Inc.
Presence & Recognition
DiaMedica Therapeutics Inc. management team will participate in four upcoming investment bank conferences in New York, including Citi Biopharma Back to School Summit, Cantor Global Healthcare Conference, Lake Street 10th Annual Best Ideas Growth (BIG10) Conference, and HC Wainwright 28th Annual Global Investment Conference.
Reported by DiaMedica Therapeutics Inc.